“Pangaea’s discovery of more undiagnosed, misdiagnosed and miscoded patients based on clinically actionable intelligence is helping healthcare providers improve patient outcomes, manage resources and collaborate with pharmaceutical companies. As a result, their customers can advance research across rare and hard-to-diagnose conditions without the need to transact data and thereby comply with privacy regulations.” – Kevin O’Leary, Regional Business Leader, Health & Life Sciences, Microsoft

Pangaea’s product platform combines artificial intelligence (AI) and clinical guidelines to characterize and find more undiagnosed and miscoded patients leading to improved outcomes, revenues and screening. Pangaea overcomes the challenges that limit collaboration between healthcare and pharmaceuticals, such as strict privacy regulations and working on a single project based approach, providing a product platform to find and connect to more patients across 7,000 hard-to-diagnose conditions in a scalable, financially sustainable, privacy-preserving manner within only 8-10 weeks, as opposed to the conventional timeline of 9-12 months. This is achieved by Pangaea’s product platform automating the process of clinicians manually reviewing patient records, which currently takes up 52% of their workday. This improves efficiency and accuracy compared to manual, metadata-based (e.g. ICD), or Natural Language Processing (NLP) approaches. This improved efficiency enhances downstream clinical assessments, timely diagnosis and appropriate care for more patients.

Collaboration with the NHS

For example, motivated by two global pharmaceutical companies seeking to connect to more cachectic cancer patients for trial and commercial purposes, Pangaea’s product was deployed by the UK’s NHS. This led to the discovery of 6x more miscoded cachectic cancer patients compared to ICD and NLP approaches, halving treatment costs from £10,000 to £5,000, which means a £1 billion annual savings for the NHS in the context of the 200,000 such patients in the UK each year. These results were presented by the Chairman of NHS at JP Morgan Health Conference and ASCO 2023.

$110 Million Grant for AI in Medicine

Most recently, Pangaea’s founder, Professor Yike Guo has won a grant for $110 million to continue its R&D work in developing Large Language models (LLMs) in medicine, which will allow it to further enhance its product to truly realize the promise of precision medicine and preventative health.

Clinically Proven Benefits

Pharmaceuticals:

• 22x higher revenue potential by finding more suitable patients for commercial therapies & trials
• 5x more trials matched to patients
• Discovered clinical relationships between drugs, features & adverse events for pharmacovigilance & drug discovery
• Saved 90% time & costs by automatically summarizing intelligence into clinical narratives for regulatory reports – Presented by global pharmaceutical company at Bio-IT World

Healthcare:

• Improved patient outcomes by finding 6x more undiagnosed and miscoded patients for screening & clinical care
• 50% reduced treatment costs by finding more undiagnosed & miscoded patients
• 4x higher revenue by reconciling ICD codes
• Improved resource allocation by predicting patient prognosis and journey – Published in the British Medical Journal
• Measured health inequity and bias based on patient records and genomic testing results – Presented by US oncologists at Bio-IT World & AACR

Pangaea’s product deployment on Azure benefits over 140,000 pharmaceutical and healthcare providers globally on Azure. With Azure’s HIPAA certification and data kept within its residing environment, full privacy regulation compliance is ensured.

To learn more, please contact us at info@pangaeadata.ai